If You Want Better Adherence, Start with Social Health

Pharma does not have an access problem alone—it has an action problem. The industry has built sophisticated systems to help patients get on treatment: copay support, benefits verification, reimbursement assistance, nurse hotlines, and refill reminders. These programs matter—they remove friction, improve access, and solve real operational barriers. And yet patients still fall away.

Across therapeutic areas, up to 50% of patients do not take medications as prescribed and many never initiate treatment or discontinue too early. At the same time, more than 40% of US adults are affected by weak social connection, and low social support is associated with a 50% higher risk of medication non-adherence.

This is not a fringe issue. In his 2023 advisory, the US Surgeon General warned that the health impact of social disconnection is comparable to smoking up to 15 cigarettes a day.

Behavioral factors—especially emotional isolation and lack of peer support—are among the largest drivers of non-adherence, and the least addressed. (Figure 1)

That should tell us something important: information and logistics are necessary but they are not enough.

Most patient support programs are designed around transactional needs. They help patients navigate cost, coverage, prior authorization, and access to information. But the moments that determine whether someone actually starts treatment, stays confident, and remains on therapy are rarely just transactional—they’re emotional, behavioral, and social.

Patients do not drop off because they lack information. They drop off because fear creeps in, confidence fades, and managing treatment alone becomes too heavy to sustain.

What many patients need in those moments is not more content. They need reinforcement from someone who understands the experience because they have lived it.

That is the power of peer connection and the gap traditional patient support programs rarely address.

“When a patient connects with someone who shares the same condition, the same challenges, or the same treatment journey, support becomes more than encouragement—it becomes credible, relevant, and actionable.”

Figure 1. Behavior Factors Are The Largest Drivers of Treatment Non-Adherence

 

“The US Surgeon General warned that the health impact of social disconnection is comparable to smoking up to 15 cigarettes a day.”

When a patient connects with someone who shares the same condition, the same challenges, or the same treatment journey, support becomes more than encouragement—it becomes credible, relevant, and actionable. A newly diagnosed patient can hear from someone who has already made the leap.

A patient considering stopping can hear from someone who got through the same difficult stretch and stayed on therapy. That kind of connection does something brand websites and reminder programs cannot do on their own: it builds belief, motivation, and self-efficacy.

This is where social health becomes a strategic lever—not a soft wellness concept. It is a measurable driver of behavior and outcomes that determines whether patients start and stay on treatment. It reflects whether patients have access to meaningful support, especially from peers with shared lived experience who can provide reassurance, perspective, and encouragement.

For pharmaceutical marketers, this is not simply a patient experience issue. It is a performance issue tied directly to initiation, adherence, and real-world outcomes.

The next era of patient support will not replace transactional services. It will strengthen them with something more human and more powerful: structured peer support from people who know what patients are going through; because solving for access and providing information may start treatment, but human connection keeps it going.